Header Logo

Connection

Michael Cookson to Middle Aged

Back to Details
This is a "connection" page, showing publications Michael Cookson has written about Middle Aged.
Michael Cookson
Connection Strength
2.164
Middle Aged
  1. Advances in the management of castration resistant prostate cancer. BMJ. 2016 Oct 17; 355:i4405.
    View in: PubMed
    Score: 0.060
  2. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. 2015 Jan; 67(1):165-170.
    View in: PubMed
    Score: 0.050
  3. A 57-year-old man with a history of prostatectomy and pelvic irradiation presents with recurrent urinary tract infections, hematuria, and pelvic pain. Urology. 2013 Feb; 81(2):221-5.
    View in: PubMed
    Score: 0.047
  4. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol. 2013 Aug; 31(6):871-7.
    View in: PubMed
    Score: 0.042
  5. Comparison of transfusion requirements between open and robotic-assisted laparoscopic radical prostatectomy. BJU Int. 2010 Oct; 106(7):1036-40.
    View in: PubMed
    Score: 0.038
  6. Open renal biopsy: comorbidities and complications in a contemporary series. BJU Int. 2010 Jul; 106(1):102-6.
    View in: PubMed
    Score: 0.037
  7. Urinary diversion trends at a high volume, single American tertiary care center. J Urol. 2009 Nov; 182(5):2369-74.
    View in: PubMed
    Score: 0.037
  8. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. BJU Int. 2009 Oct; 104(8):1091-7.
    View in: PubMed
    Score: 0.036
  9. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer. J Urol. 2008 Aug; 180(2):451-9; discussion 460.
    View in: PubMed
    Score: 0.034
  10. Effect of a large prostate gland on open and robotically assisted laparoscopic radical prostatectomy. BJU Int. 2008 May; 101(9):1140-4.
    View in: PubMed
    Score: 0.034
  11. Contemporary open radical cystectomy: analysis of perioperative outcomes. J Urol. 2008 Apr; 179(4):1313-8; discussion 1318.
    View in: PubMed
    Score: 0.033
  12. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J Urol. 2007 Dec; 178(6):2385-9; discussion 2389-90.
    View in: PubMed
    Score: 0.032
  13. Urothelial carcinoma of the bladder metastatic to bone marrow presenting as isolated thrombocytopenia. ScientificWorldJournal. 2007 Jun 12; 7:1000-3.
    View in: PubMed
    Score: 0.032
  14. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 2006 Jun; 97(6):1169-72.
    View in: PubMed
    Score: 0.029
  15. Safely reducing length of stay after open radical retropubic prostatectomy under the guidance of a clinical care pathway. Cancer. 2005 Aug 15; 104(4):747-51.
    View in: PubMed
    Score: 0.028
  16. Performance-enhancing supplement use in patients with testicular cancer. Urology. 2005 Aug; 66(2):242-5.
    View in: PubMed
    Score: 0.028
  17. A pilot randomized clinical trial of a smartphone-based application to support at-home PSA screening and culturally tailored prostate cancer education for African American men: A study protocol. Contemp Clin Trials. 2024 Dec; 147:107737.
    View in: PubMed
    Score: 0.026
  18. Ileal conduit urinary diversion in patients with previous history of abdominal/pelvic irradiation. World J Urol. 2004 Oct; 22(4):272-6.
    View in: PubMed
    Score: 0.026
  19. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
    View in: PubMed
    Score: 0.026
  20. Predicting blood loss and transfusion requirements during radical prostatectomy: the significant negative impact of increasing body mass index. J Urol. 2004 May; 171(5):1861-5.
    View in: PubMed
    Score: 0.026
  21. Increased body mass index predicts increased blood loss during radical cystectomy. J Urol. 2004 Mar; 171(3):1077-9.
    View in: PubMed
    Score: 0.025
  22. Complications of contemporary radical nephrectomy: comparison of open vs. laparoscopic approach. Urol Oncol. 2004 Mar-Apr; 22(2):121-6.
    View in: PubMed
    Score: 0.025
  23. Primary renal carcinoid tumor. J Urol. 2004 Jan; 171(1):338.
    View in: PubMed
    Score: 0.025
  24. Health related quality of life in patients treated with radical cystectomy and urinary diversion for urothelial carcinoma of the bladder: development and validation of a new disease specific questionnaire. J Urol. 2003 Nov; 170(5):1926-30.
    View in: PubMed
    Score: 0.025
  25. Decreasing blood loss in patients treated with radical cystectomy: a prospective randomizes trial using a new stapling device. J Urol. 2003 Mar; 169(3):951-4.
    View in: PubMed
    Score: 0.024
  26. Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J Urol. 2003 Jan; 169(1):101-4.
    View in: PubMed
    Score: 0.023
  27. The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA. Urol Oncol. 2002 Sep-Oct; 7(5):195-8.
    View in: PubMed
    Score: 0.023
  28. Beneficial impact of a clinical care pathway in patients with testicular cancer undergoing retroperitoneal lymph node dissection. J Urol. 2002 Jul; 168(1):87-92.
    View in: PubMed
    Score: 0.022
  29. Pathological findings of gynecologic organs obtained at female radical cystectomy. J Urol. 2002 Jul; 168(1):147-9.
    View in: PubMed
    Score: 0.022
  30. Health related quality of life assessment after radical cystectomy: comparison of ileal conduit with continent orthotopic neobladder. J Urol. 2002 Jul; 168(1):164-7.
    View in: PubMed
    Score: 0.022
  31. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol. 2002 May; 167(5):2032-5; discussion 2036.
    View in: PubMed
    Score: 0.022
  32. Eosinophilic cystitis presenting as a recurrent symptomatic bladder mass following intravesical mitomycin C therapy. J Urol. 2002 Apr; 167(4):1795.
    View in: PubMed
    Score: 0.022
  33. Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol. 2002 Feb; 167(2 Pt 1):502-5.
    View in: PubMed
    Score: 0.022
  34. Estimated blood loss and transfusion requirements of radical cystectomy. J Urol. 2001 Dec; 166(6):2151-4.
    View in: PubMed
    Score: 0.022
  35. Intrarectal lidocaine during transrectal prostate biopsy: results of a prospective double-blind randomized trial. J Urol. 2001 Dec; 166(6):2178-80.
    View in: PubMed
    Score: 0.022
  36. Health related quality of life assessment after radical prostatectomy in men with prostate specific antigen only recurrence. J Urol. 2001 Dec; 166(6):2286-90.
    View in: PubMed
    Score: 0.022
  37. Prediction of tumour volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores. BJU Int. 2001 Nov; 88(7):722-6.
    View in: PubMed
    Score: 0.021
  38. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. J Urol. 2022 01; 207(1):70-76.
    View in: PubMed
    Score: 0.021
  39. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World J Urol. 2021 Dec; 39(12):4345-4354.
    View in: PubMed
    Score: 0.021
  40. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001 Aug; 166(2):490-3.
    View in: PubMed
    Score: 0.021
  41. Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen. J Urol. 2001 Feb; 165(2):455-8.
    View in: PubMed
    Score: 0.020
  42. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
    View in: PubMed
    Score: 0.020
  43. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. BJU Int. 2021 07; 128(1):79-87.
    View in: PubMed
    Score: 0.020
  44. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int. 2021 05; 127(5):528-537.
    View in: PubMed
    Score: 0.020
  45. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020 06 04; 382(23):2187-2196.
    View in: PubMed
    Score: 0.019
  46. 8q24 genetic variation and comprehensive haplotypes altering familial risk of prostate cancer. Nat Commun. 2020 03 23; 11(1):1523.
    View in: PubMed
    Score: 0.019
  47. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urol Oncol. 2020 07; 38(7):639.e1-639.e9.
    View in: PubMed
    Score: 0.019
  48. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urol Oncol. 2020 01; 38(1):3.e17-3.e27.
    View in: PubMed
    Score: 0.019
  49. Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. J Urol. 2020 03; 203(3):522-529.
    View in: PubMed
    Score: 0.019
  50. Risk of Ovarian Malignancy in Patients Undergoing Radical Cystectomy for Bladder Cancer. Urology. 2019 Jan; 123:181-185.
    View in: PubMed
    Score: 0.017
  51. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018 06 23; 391(10139):2525-2536.
    View in: PubMed
    Score: 0.017
  52. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. World J Urol. 2019 Jan; 37(1):165-172.
    View in: PubMed
    Score: 0.017
  53. Effects of primary care physician density, urologist presence, and insurance status on stage of diagnosis for urologic malignancies. Cancer Epidemiol. 2018 02; 52:10-14.
    View in: PubMed
    Score: 0.016
  54. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997 Jul; 158(1):62-7.
    View in: PubMed
    Score: 0.016
  55. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy. Urology. 1997 Jun; 49(6):887-93.
    View in: PubMed
    Score: 0.016
  56. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Br J Urol. 1997 Mar; 79(3):432-8.
    View in: PubMed
    Score: 0.016
  57. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol. 1997 Feb; 157(2):559-62.
    View in: PubMed
    Score: 0.015
  58. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. Urol Oncol. 2017 05; 35(5):286-293.
    View in: PubMed
    Score: 0.015
  59. Short term complications from transurethral resection of bladder tumor. Can J Urol. 2016 Apr; 23(2):8198-203.
    View in: PubMed
    Score: 0.015
  60. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels. J Urol. 1995 Sep; 154(3):1070-3.
    View in: PubMed
    Score: 0.014
  61. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. Am J Pathol. 2015 May; 185(5):1385-95.
    View in: PubMed
    Score: 0.014
  62. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urol Oncol. 2015 Jan; 33(1):21.e11-21.e17.
    View in: PubMed
    Score: 0.013
  63. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb; 67(2):241-9.
    View in: PubMed
    Score: 0.013
  64. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. Urology. 2014 Jun; 83(6):1309-15.
    View in: PubMed
    Score: 0.013
  65. An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility. Am J Hum Genet. 2014 Mar 06; 94(3):395-404.
    View in: PubMed
    Score: 0.013
  66. Hormonal therapy for metastatic prostate cancer: issues of timing and total androgen ablation. South Med J. 1994 Jan; 87(1):1-6.
    View in: PubMed
    Score: 0.012
  67. Racial variation in the quality of surgical care for bladder cancer. Cancer. 2014 Apr 01; 120(7):1018-25.
    View in: PubMed
    Score: 0.012
  68. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology. 2014 Jan; 83(1):75-80.
    View in: PubMed
    Score: 0.012
  69. Blood loss associated with radical cystectomy: a prospective, randomized study comparing Impact LigaSure vs. stapling device. Urol Oncol. 2014 Jan; 32(1):45.e11-5.
    View in: PubMed
    Score: 0.012
  70. Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns. J Urol. 2014 Feb; 191(2):329-34.
    View in: PubMed
    Score: 0.012
  71. Analysis of microsurgical penile revascularization results by etiology of impotence. J Urol. 1993 May; 149(5 Pt 2):1308-12.
    View in: PubMed
    Score: 0.012
  72. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol. 2013 Jun; 189(6):2039-46.
    View in: PubMed
    Score: 0.012
  73. Long-term results with vacuum constriction device. J Urol. 1993 Feb; 149(2):290-4.
    View in: PubMed
    Score: 0.012
  74. Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. J Urol. 2013 Feb; 189(2):507-13.
    View in: PubMed
    Score: 0.011
  75. ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. BJU Int. 2012 Dec; 110(11 Pt B):E641-6.
    View in: PubMed
    Score: 0.011
  76. Racial variation in the quality of surgical care for prostate cancer. J Urol. 2012 Oct; 188(4):1279-85.
    View in: PubMed
    Score: 0.011
  77. Voiding function in women with orthotopic neobladder urinary diversion. J Urol. 2012 Jul; 188(1):200-4.
    View in: PubMed
    Score: 0.011
  78. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One. 2012; 7(5):e36669.
    View in: PubMed
    Score: 0.011
  79. Recovery of urinary function after radical prostatectomy: identification of trajectory cluster groups. J Urol. 2012 Apr; 187(4):1346-51.
    View in: PubMed
    Score: 0.011
  80. National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol. 2012 Mar; 187(3):816-21.
    View in: PubMed
    Score: 0.011
  81. Spurious elevation of serum PSA after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies. Prostate Cancer Prostatic Dis. 2012 Jun; 15(2):182-8.
    View in: PubMed
    Score: 0.011
  82. Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol. 2011 Dec; 186(6):2221-7.
    View in: PubMed
    Score: 0.011
  83. Tumour size, tumour complexity, and surgical approach are associated with nephrectomy type in small renal cortical tumours treated electively. BJU Int. 2012 Jun; 109(11):1607-13.
    View in: PubMed
    Score: 0.011
  84. Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. Urology. 2011 Jul; 78(1):99-104.
    View in: PubMed
    Score: 0.010
  85. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol. 2011 Jun; 59(6):923-8.
    View in: PubMed
    Score: 0.010
  86. The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Causes Control. 2011 Mar; 22(3):417-26.
    View in: PubMed
    Score: 0.010
  87. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods. World J Urol. 2011 Feb; 29(1):15-20.
    View in: PubMed
    Score: 0.010
  88. Smaller prostate size predicts high grade prostate cancer at final pathology. J Urol. 2010 Sep; 184(3):930-7.
    View in: PubMed
    Score: 0.010
  89. Comparative analysis of whole mount processing and systematic sampling of radical prostatectomy specimens: pathological outcomes and risk of biochemical recurrence. J Urol. 2010 Oct; 184(4):1334-40.
    View in: PubMed
    Score: 0.010
  90. Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival. J Urol. 2010 Mar; 183(3):990-6.
    View in: PubMed
    Score: 0.009
  91. Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. J Urol. 2009 Dec; 182(6):2695-701.
    View in: PubMed
    Score: 0.009
  92. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy. J Urol. 2009 Nov; 182(5):2291-5.
    View in: PubMed
    Score: 0.009
  93. Immediate surgical outcomes for radical prostatectomy in the University HealthSystem Consortium Clinical Data Base: the impact of hospital case volume, hospital size and geographical region on 48,000 patients. BJU Int. 2009 Nov; 104(10):1442-5.
    View in: PubMed
    Score: 0.009
  94. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. BJU Int. 2009 Oct; 104(7):934-7.
    View in: PubMed
    Score: 0.009
  95. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J Urol. 2009 May; 181(5):2064-70.
    View in: PubMed
    Score: 0.009
  96. Primary endoscopic management versus open revision of ureteroenteric anastomotic strictures after urinary diversion--single institution contemporary series. J Endourol. 2009 Mar; 23(3):551-5.
    View in: PubMed
    Score: 0.009
  97. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Cancer. 2009 Feb 15; 115(4):770-5.
    View in: PubMed
    Score: 0.009
  98. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol. 2009 Feb; 181(2):540-5; discussion 546.
    View in: PubMed
    Score: 0.009
  99. Prognostic factors in T3b renal cell carcinoma. World J Urol. 2009 Feb; 27(1):75-9.
    View in: PubMed
    Score: 0.009
  100. Waiting time from initial urological consultation to nephrectomy for renal cell carcinoma--does it affect survival? J Urol. 2008 Jun; 179(6):2152-7.
    View in: PubMed
    Score: 0.008
  101. Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men. Prostate Cancer Prostatic Dis. 2008; 11(3):264-9.
    View in: PubMed
    Score: 0.008
  102. Association of procedure volume with radical cystectomy outcomes in a nationwide database. J Urol. 2007 Oct; 178(4 Pt 1):1418-21; discussion 1421-2.
    View in: PubMed
    Score: 0.008
  103. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007 Nov; 28(6):763-9.
    View in: PubMed
    Score: 0.008
  104. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007 Jul; 178(1):68-73; discussion 73.
    View in: PubMed
    Score: 0.008
  105. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May; 177(5):1777-81.
    View in: PubMed
    Score: 0.008
  106. Comparison of length of hospital stay between radical retropubic prostatectomy and robotic assisted laparoscopic prostatectomy. J Urol. 2007 Mar; 177(3):929-31.
    View in: PubMed
    Score: 0.008
  107. Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia. Cancer Causes Control. 2007 May; 18(4):375-84.
    View in: PubMed
    Score: 0.008
  108. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis. 2007; 10(2):137-42.
    View in: PubMed
    Score: 0.008
  109. Toxicity following high-dose salvage radiotherapy after radical prostatectomy. BJU Int. 2007 Mar; 99(3):529-33.
    View in: PubMed
    Score: 0.008
  110. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer. 2006 Nov 15; 107(10):2361-7.
    View in: PubMed
    Score: 0.008
  111. Sperm banking: use and outcomes in patients treated for testicular cancer. BJU Int. 2007 Jan; 99(1):33-6.
    View in: PubMed
    Score: 0.008
  112. Patterns of initial transitional cell recurrence in patients after cystectomy. J Urol. 2006 Jun; 175(6):2054-7.
    View in: PubMed
    Score: 0.007
  113. Morbidity and efficacy of genitofemoral nerve grafts with radical retropubic prostatectomy. Urology. 2006 Apr; 67(4):789-92.
    View in: PubMed
    Score: 0.007
  114. Significance of atypical and suspicious small acinar proliferations, and high grade prostatic intraepithelial neoplasia on prostate biopsy: implications for cancer detection and biopsy strategy. J Urol. 2006 Mar; 175(3 Pt 1):929-33; discussion 933.
    View in: PubMed
    Score: 0.007
  115. Robotic assisted laparoscopic radical prostatectomy versus retropubic radical prostatectomy: a prospective assessment of postoperative pain. J Urol. 2005 Sep; 174(3):912-4; discussion 914.
    View in: PubMed
    Score: 0.007
  116. Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes. J Urol. 2005 Jun; 173(6):1897-902.
    View in: PubMed
    Score: 0.007
  117. Urethral recurrence in patients following orthotopic urinary diversion. J Urol. 2004 Oct; 172(4 Pt 1):1338-41.
    View in: PubMed
    Score: 0.007
  118. Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy. J Urol. 2004 Sep; 172(3):882-4.
    View in: PubMed
    Score: 0.007
  119. Complications of inguinal and pelvic lymphadenectomy for squamous cell carcinoma of the penis: a contemporary series. J Urol. 2004 Aug; 172(2):494-7.
    View in: PubMed
    Score: 0.006
  120. Adverse prognostic significance of capsular incision with radical retropubic prostatectomy. J Urol. 2004 Jul; 172(1):119-23.
    View in: PubMed
    Score: 0.006
  121. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol. 2004 Feb; 171(2 Pt 1):646-51.
    View in: PubMed
    Score: 0.006
  122. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol. 2003 Oct; 170(4 Pt 1):1085-7.
    View in: PubMed
    Score: 0.006
  123. Single-center comparison of purely laparoscopic, hand-assisted laparoscopic, and open radical nephrectomy in patients at high anesthetic risk. J Endourol. 2003 Apr; 17(3):161-7.
    View in: PubMed
    Score: 0.006
  124. Partial nephrectomy safely preserves renal function in patients with a solitary kidney. J Urol. 2003 Jan; 169(1):79-81.
    View in: PubMed
    Score: 0.006
  125. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol. 2003 Jan; 169(1):145-7; discussion 147-8.
    View in: PubMed
    Score: 0.006
  126. Orthotopic neobladder following radical cystectomy in patients with high perioperative risk and co-morbid medical conditions. J Urol. 2002 Dec; 168(6):2454-6.
    View in: PubMed
    Score: 0.006
  127. Preservation of the anterior vaginal wall during female radical cystectomy with orthotopic urinary diversion: technique and results. J Urol. 2002 Oct; 168(4 Pt 1):1442-5.
    View in: PubMed
    Score: 0.006
  128. Causes of increased length of stay following radical cystectomy. Urol Nurs. 2002 Oct; 22(5):319-23, 339.
    View in: PubMed
    Score: 0.006
  129. Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J Urol. 2002 May; 167(5):2012-6.
    View in: PubMed
    Score: 0.006
  130. Routine postoperative intensive care monitoring is not necessary after radical cystectomy. J Urol. 2002 Mar; 167(3):1321-4.
    View in: PubMed
    Score: 0.005
  131. Causes of increased hospital stay after radical cystectomy in a clinical pathway setting. J Urol. 2002 Jan; 167(1):208-11.
    View in: PubMed
    Score: 0.005
  132. Clinical and pathologic findings in hereditary spastic paraparesis with spastin mutation. Neurology. 2000 Jul 12; 55(1):89-94.
    View in: PubMed
    Score: 0.005
  133. Repeat transrectal ultrasound-guided prostate biopsy: a strategy to improve the reliability of needle biopsy grading in patients with well-differentiated prostate cancer. Urology. 1998 Oct; 52(4):659-62.
    View in: PubMed
    Score: 0.004
  134. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology. 1997 Mar; 49(3A Suppl):46-55.
    View in: PubMed
    Score: 0.004
  135. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol. 1996 Oct; 156(4):1286-7.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.